Limitations of treatments available for the management of Type 2 diabetes: Results from an international survey of physicians

Southwell, Angela; Eckland, D.J.A.

doi:10.1002/pdi.1960150408

Cited by 4 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most patients eventually require exogenous insulin injections to attain glycemic control targets (1). Despite this, patients and physicians appear to be hesitant to use insulin, and, consequently, patients remain in poor glycemic control (2)(3)(4)(5). Needle anxiety is one of the factors associated with this reluctance (6,7); therefore, new routes of insulin administration could be used to achieve and maintain optimal glycemic control.…”

mentioning

confidence: 99%

Intensive Therapy With Inhaled Insulin via the AERx Insulin Diabetes Management System

et al. 2004

View full text Add to dashboard Cite

OBJECTIVE -To compare the glycemic control of inhaled insulin via the AERx insulin diabetes management system (iDMS) with that of subcutaneous (SC) insulin, both combined with NPH insulin at bedtime, in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS -The AERx iDMS uses a liquid insulin formulation to achieve flexible precise mealtime dosing (with increments corresponding to 1 IU administered subcutaneously) and ensures insulin delivery only when the breathing technique is optimal. This trial in patients with type 2 diabetes compared the glycemic control (HbA 1c ) achieved by inhaled insulin administered via AERx iDMS with that using SC insulin. This was a randomized, 12-week, open-label, parallel, multicenter, multinational trial in 107 nonsmoking patients with type 2 diabetes (mean age 59 years, mean duration of diabetes 11.9 years). Patients were randomized to receive either inhaled fast-acting human insulin via AERx iDMS immediately before meals or SC fast-acting human insulin administered 30 min before meals, both in combination with evening NPH insulin.RESULTS -Baseline and demographic characteristics were similar between the two groups. There was no statistically significant difference in HbA 1c between the AERx and SC groups after 12 weeks of treatment (7.84 Ϯ 0.77 vs. 7.76 Ϯ 0.77%, P ϭ 0.60). Fasting serum glucose was significantly lower in the AERx group compared with the SC group by the end of the trial (8.9 Ϯ 3.8 vs. 10.8 Ϯ 3.7 mmol/l, P ϭ 0.01) with a similar NPH dose in the two groups (0.23 vs. 0.23 IU/kg, P ϭ 0.93). There were no statistically significant differences between the two groups in the intra-subject variability of fasting or prandial blood glucose increment. Adverse events were similar in the two groups. No major safety concerns were raised during the trial.CONCLUSIONS -In patients with type 2 diabetes, preprandial inhaled insulin via AERx iDMS is as effective as preprandial SC insulin injection in achieving glycemic control with similar tolerability. Diabetes Care 27:162-167, 2004M any patients with type 2 diabetes initially achieve adequate glycemic control with diet, exercise, and oral antidiabetic medication. However, most patients eventually require exogenous insulin injections to attain glycemic control targets (1). Despite this, patients and physicians appear to be hesitant to use insulin, and, consequently, patients remain in poor glycemic control (2-5). Needle anxiety is one of the factors associated with this reluctance (6,7); therefore, new routes of insulin administration could be used to achieve and maintain optimal glycemic control.Presently, the alternatives to subcutaneous (SC) injections of insulin are limited. The only existing clinical alternative is continuous SC insulin infusion, or insulin administered by means of an implantable pump. This alternative is mainly recommended and used in patients with type 1 diabetes. One recent development is that of inhaled insulin systems, and current published data have shown the clinical viability of inhaled insulin in...

show abstract

mentioning

confidence: 99%

Intensive Therapy With Inhaled Insulin via the AERx Insulin Diabetes Management System

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Worldwide studies have shown that hyperglycemia is a symptom of metabolic disorders like diabetes. In recent years the treatment goal is focused on rectifying the metabolic state and lowering the risk of micro and macrovascular complications as well [8].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Quality of Life Assessment of ‘Kapiva Dia Free Juice’ Treatment as an Adjuvant for Type 2 Diabetes

Soni¹,

Sharma²,

Rao³

2023

JDMC

View full text Add to dashboard Cite

Background: Diabetes mellitus (DM) is characterized by chronic hyperglycemia, defects in insulin secretion, action, or both, and is fuelled by the obesity epidemic. Conventional medication offers side effects and insufficient glycaemic management in chronic use. Safe and effective adjuvants from the natural source need to be studied clinically. Methods: 30 patients of diabetes mellitus were enrolled in the study for 3 months. The interventional product kapiva dia free juice was administered twice daily along with the conventional antidiabetics. Fasting and post prandial blood glucose were measured every month while HbA1c, serum C-peptide level, BMI, biochemical and hematological investigations on baseline and day 90. Data was analysed using SPSS (version 19). Result: HbA1c was reduced significantly by 11.11% after 90 days of treatment. The percentage of significant reduction in fasting and post prandial blood glucose was 30.05% and 33.11% respectively. BMI was significantly reduced by 2.92% with average weight reduction of 2.17 kg. Insulin resistance was also reduced significantly which was evident by lowered C-Peptide by 28.81%. All the biochemical and hematological parameters were found within normal range and no adverse events were reported related to the investigational product. Conclusion: Kapiva dia free juice is an effective adjuvant treatment in diabetes mellitus which can improve glycemic control, reduce BMI and insulin resistance. This reduces cardiac risk and improves antidiabetic medication effectiveness. All hematological parameters were well within limits in the study which indicates the safety of the product.

show abstract

Validation of standardized polyherbal formulation in the management of type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial

Pandya

Savaliya

Thummar

et al. 2022

J Diabetes Metab Disord

View full text Add to dashboard Cite

Limitations of treatments available for the management of Type 2 diabetes: Results from an international survey of physicians

Cited by 4 publications

References 10 publications

Intensive Therapy With Inhaled Insulin via the AERx Insulin Diabetes Management System

Intensive Therapy With Inhaled Insulin via the AERx Insulin Diabetes Management System

Efficacy and Quality of Life Assessment of ‘Kapiva Dia Free Juice’ Treatment as an Adjuvant for Type 2 Diabetes

Validation of standardized polyherbal formulation in the management of type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial

Contact Info

Product

Resources

About